Drugs / LY3866288
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06644378 | Oct 2024 → Jan 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06641037 | Oct → Dec 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3866288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641037 ↗ |
| Route | Oral | “The study drug will be administered orally.” NCT06641037 ↗ |